

## Antigen-specific T-cell receptor signatures of cytomegalovirus infection

5 Alina Huth,<sup>\*,†,¶</sup> Xiaoling Liang,<sup>\*,‡,¶</sup> Stefan Krebs,<sup>§</sup> Helmut Blum,<sup>§</sup> Andreas Moosmann<sup>\*,†</sup>

\* DZIF Research Group "Host Control of Viral Latency and Reactivation" (HOCOVLAR),  
Research Unit Gene Vectors, Helmholtz Zentrum München, Munich, Germany

† German Center for Infection Research (DZIF – Deutsches Zentrum für

10 Infektionsforschung), Munich, Germany

‡ Present address: HRYZ Biotech Co., Shenzhen, China

§ Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-  
Maximilians-Universität München, Munich, Germany

15

¶ These authors contributed equally to this work.

This work was supported by Deutsche Forschungsgemeinschaft (SFB-TR36, Project A4).

20 Address correspondence and reprint requests to Dr. Andreas Moosmann, Marchioninistr. 25,  
81377 München, Germany. E-mail address: [andreas.moosmann@helmholtz-muenchen.de](mailto:andreas.moosmann@helmholtz-muenchen.de)

25

## Abstract

Cytomegalovirus (CMV) is a prevalent human pathogen. The virus cannot be eliminated from the body, but is kept in check by CMV-specific T cells. Patients with an insufficient T-cell response, such as transplant recipients, are at high risk of developing CMV disease. However, the CMV-specific T-cell repertoire is complex, and is not yet clear which T cells protect best against virus reactivation and disease. Here we present a highly resolved characterization of CMV-specific CD8<sup>+</sup> T cells based on enrichment by specific peptide stimulation and mRNA sequencing of their T-cell receptor  $\beta$  chains (TCR $\beta$ ). Our analysis included recently identified T-cell epitopes restricted through HLA-C, whose presentation is resistant to viral immunomodulation, and well-studied HLA-B-restricted epitopes. In 8 healthy virus carriers, we identified a total of 1052 CMV-specific TCR $\beta$  chains. HLA-C-restricted, CMV-specific TCR $\beta$  clonotypes the *ex vivo* T-cell response, and contributed the highest-frequency clonotype of the entire repertoire in 2 of 8 donors. We analyzed sharing and similarity of CMV-specific TCR $\beta$  sequences and identified 63 public or related sequences belonging to 17 public TCR $\beta$  families. In our cohort and in an independent cohort of 352 donors, the cumulative frequency of these public TCR $\beta$  family members was a highly discriminatory indicator of carrying both CMV infection and the relevant HLA type. Based on these findings, we propose CMV-specific TCR $\beta$  signatures as a biomarker for an antiviral T-cell response to identify patients in need of treatment and to guide future development of immunotherapy.

## Introduction

50

Like other members of the herpesvirus family, human cytomegalovirus (CMV) infects its carriers for life, and prevention of overt disease requires a protective repertoire of virus-specific T cells (1, 2). Persons who lack such a T-cell repertoire, such as patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), are at risk of reactivating latent CMV infection, and CMV disease remains a threat to their survival and well-being (3). Conventional antiviral chemotherapy has significant adverse effects, is not universally effective, may delay viral reactivation rather than prevent it, and is subverted by viral resistance (3, 4).

55

Re-establishment of a functional and durable antiviral T-cell repertoire is expected to enable patients to control CMV infection for their lifetime. Transfer of CMV-specific T cells from immunocompetent donors to patients after allo-HSCT has yielded encouraging results over the last three decades (5, 6). However, most of these trials were of small to medium scale and without randomized controls. Preliminary reports on two recent large randomized controlled trials suggest efficacy (5), but complete analysis is not yet available.

60

Therefore, present capability to clinically exploit the CMV-specific T-cell repertoire is limited.

65

Although the CMV-specific T-cell response has been studied in great detail (7), fundamental questions remain unanswered. No consensus has been reached on which viral antigens and epitopes induce T-cell responses that directly protect against infection, and which T-cell specificities are merely correlated with the presence of other, more effective specificities (7).

70

The challenge of understanding the CMV-specific T-cell repertoire is formidable, since CMV expresses more than 200 viral proteins and has evolved multiple mechanisms to interfere with T-cell recognition by modulating cytokine and chemokine responses, antigen processing, intracellular peptide translocation, stability of HLA molecules, and more (8, 9). Moreover, human CMV shows sequence variation, and some specific T cells may recognize only certain strain-specific epitope variants (10).

75 A particularly strong CD8<sup>+</sup> T-cell response is directed to two viral antigens with contrasting functional roles and kinetics of expression: the transcription factor IE-1 and the structural protein pp65 (11, 12). Earlier data indicated that pp65-specific CD8<sup>+</sup> T cells were the most effective in attacking infected cells *in vitro* (13), whereas IE-1-specific T cells were more strongly associated with reduced viral reactivation in patients after transplantation (14, 15) and  
80 protective in the murine CMV model (16). Our recent findings suggested that viral immunoevasion is not predominantly guided by the identity of the antigen, but by the identity of the epitope and the HLA class I molecule that presents it (17, 18). For example, we identified an HLA-C-restricted CD8<sup>+</sup> T-cell epitope from IE-1 whose presentation is highly resistant to viral immunomodulation. T cells specific for this epitope are of high incidence and frequency  
85 in healthy donors (17, 18). These properties are shared (19) by a second CD8<sup>+</sup> T-cell epitope restricted through the same HLA (20); this epitope is derived from the rarely studied UL29/28-encoded CMV protein. It is unknown whether there is a causal relationship between escape of certain epitopes from viral immunomodulation and high incidence of epitope-specific T cells, and whether T cells against such epitopes are associated with protection from reactivation. To  
90 address such questions, the CMV-specific T-cell response needs to be analyzed and understood in much more detail, using methods that are of sufficient resolution to adequately cover the complexity of the repertoire. High-resolution sequencing of the T-cell receptor (TCR) is such a method.

Most human T cells express a heterodimeric  $\alpha\beta$  TCR that specifically recognizes the antigenic  
95 target, a complex of an HLA molecule and a peptide. Both chains,  $\alpha$  and  $\beta$ , have highly variable sequences. The specificity of each  $\alpha\beta$  T cell is ensured by its expression of only one TCR $\beta$  chain and one or, occasionally, two TCR $\alpha$  chains (21). Variability of TCR sequence is produced by recombination in the thymus. In the case of the human TCR $\beta$  chain, a V(D)J reading frame is produced by imprecisely joining one of 46 functional V genes, one of two short D genes, and  
100 one of 13 J genes, mostly with insertion of template-independent nucleotides between the genes

(22, 23). The sequence around these junctions encodes the CDR3, a loop that reaches out to the peptide embedded in the HLA molecule (24). The number of different TCR $\beta$  chains in the T-cell repertoire of a human being was estimated to be in the range of millions (25–27) or even hundreds of millions (28); this is only a small fraction of the diversity that is theoretically possible (22, 27). CMV-specific TCR repertoires have been studied in detail before (29–31), but most studies were limited to pp65 and HLA-C-restricted T cells were not included. The advent of massively parallel sequencing of TCR-encoding DNA or mRNA (26, 32) has now made it possible to identify the specificity-defining element of millions of T cells in a sample, and pioneering studies have applied this technique to the analysis of CMV-specific T cells (33–  
110 36).

Here we use high-resolution TCR $\beta$  sequencing to investigate the repertoire of CMV-specific CD8<sup>+</sup> T cells, focusing on previously unstudied HLA-C-restricted T cells that promise to be of high clinical interest. Specific T cells were selectively enriched by peptide-driven *in vitro* expansion; this method is transferable to settings when samples are small or HLA/peptide  
115 multimers are not available. We found that T cells specific for HLA-C-restricted CMV epitopes showed exceptional clonal dominance within the overall TCR $\beta$  repertoire. Moreover, we identified a set of public and related CMV-specific TCR $\beta$  sequences that reliably distinguished persons with or without CMV-specific T-cell immunity, immediately suggesting future application of this method in clinical immunomonitoring.

120

## Materials and Methods

### Blood donors

Human T cells were derived from anonymous peripheral blood buffy coats purchased from  
125 Institut für Transfusionsmedizin, Ulm, Germany. The institutional review board  
(Ethikkommission bei der LMU München, Project No. 17-455, 16.10.2017) has approved our  
use of anonymous human material. We did not seek or obtain consent since all material and  
data were obtained anonymously. Peripheral blood mononuclear cells (PBMCs) were isolated  
by density centrifugation and cryopreserved until use. Donors were HLA-typed at 4-digit  
130 resolution (MVZ, Martinsried, Germany). All donors were positive for HLA-B\*07:02 and  
HLA-C\*07:02. CMV status (Supplementary Table 1) was determined by anti-CMV IgG ELISA  
(Siemens).

### Peptide stimulation assay

135 The four CMV-derived peptides CRVLCCYVL (CRV, HLA-C\*07:02, IE-1), FRCPRRFCF  
(FRC, HLA-C\*07:02, UL28), RIPHERNGFTVL (RPH, HLA-B\*07:02, pp65), and  
TPRVTGGGAM (TPR, HLA-B\*07:02, pp65) (Supplementary Table 1) were separately used  
to stimulate and selectively expand virus-specific T cells from CMV-positive donors P01-P08.  
Cell culture medium was RPMI 1640 (Invitrogen) supplemented with 8% or 10% FCS (Bio-  
140 Sell or Invitrogen). Per culture, 25 million PBMCs were suspended in 2 mL cell culture medium  
containing 5 µg/ml of peptide (JPT, Berlin; ≥70% purity), incubated at 37°C for 1 hour, and  
washed three times with PBS (PAN Biotech) to remove excess peptide. PBMCs were  
resuspended in 12.5 ml cell culture medium supplemented with 50 U/ml IL-2 (Proleukin;  
Novartis) and distributed at 2.5 ml per well to a 12-well plate. The plate was incubated at 37°C  
145 and 5% CO<sub>2</sub>. After 6±1 days, the cells of each well were resuspended, distributed to two wells,

and 1 ml of fresh culture medium supplemented with IL-2 was added to each well. Cells were harvested at day 10 of culture.

### **T-cell stimulation with autologous mini-LCLs**

150 PBMCs from three healthy donors (P01-P03) were infected with empty mini-Epstein-Barr viruses encoding pp65, IE-1, or no CMV protein (37). The resulting transformed B cell lines (mini-lymphoblastoid cell lines, mini-LCLs) were maintained in RPMI 1640 medium supplemented with 8% or 10% FCS. For the stimulation assay, mini-LCLs were  $\gamma$ -irradiated with 50 Gy in a Cs-137 device. Subsequently, 150,000 mini-LCL cells were combined with 6  
155 million PBMCs in 3 mL RPMI/FCS per replicate in a 12-well plate, in four replicates per culture. After 9 days and then every 7 days, the T cells were restimulated: cultures were harvested, washed, counted, and 3 million T cells per well (12-well plate) were coincubated with 1 million irradiated mini-LCLs in medium with 50 U/ml IL-2. At day 30, cultures were harvested to analyze T cells.

160

### **TCR $\beta$ library preparation**

Where indicated (Supplementary Table 2), CD8<sup>+</sup> T cells were enriched from PBMCs or T-cell cultures by magnetic separation with CD8 MicroBeads and MS or LS Columns (Miltenyi Biotech).

165 Total RNA was extracted from PBMCs, T-cell cultures, or CD8-enriched T cells using the Qiagen RNeasy Kit (Qiagen). 1  $\mu$ g RNA per sample was reversely transcribed to cDNA with the QuantiTect Reverse Transcription Kit (Qiagen) using a primer designed to target both the C $\beta$ 1 and C $\beta$ 2 regions of the TCR RNA (5'-GCACC TCCTT CCCAT TCAC-3'). cDNA was amplified in two subsequent PCRs using *Pfu* DNA polymerase on a thermocycler (Biometra T  
170 Gradient). Both PCRs were initiated at 95°C for 2 min; cycles consisted of incubation at 95°C (30 sec), 65°C (30 sec), and 72°C (60 sec); final elongation was at 72°C (10 min). The first

reaction was a multiplex PCR with 42 distinct forward primers that bind to the V $\beta$  region and cover all possible human TCR V $\beta$  segments, and a reverse primer that anneals to the C $\beta$ 1 and C $\beta$ 2 regions; the C $\beta$  primer was optimized for this protocol, V $\beta$  binding sites were mostly taken  
175 from established protocols (26). Forward (V $\beta$ ) and reverse (C $\beta$ ) primers carried sequences complementary to the Illumina Read 2 and Read 1 priming sequence, respectively. To enhance the nucleotide diversity of TCR $\beta$  reads, facilitate cluster recognition and avoid artefacts, three different forms of the reverse primer were used, with 0, 1 or 2 degenerated nucleotides (N) inserted between the C $\beta$ -binding sequence and the Illumina Read 1 sequence. All primers were  
180 used in equimolar amounts (a total of 10  $\mu$ M; for primer sequences see Supplementary Table 1). The first PCR consisted of only 10 amplification cycles to minimize PCR amplification bias. The second PCR was performed with index primers (NEBNext Multiplex Oligos for Illumina; New England BioLabs), to attach barcodes and the i5 and i7 adapters for cluster generation on the Illumina flow cell (Figure 1B). After each PCR step, the PCR product was purified using  
185 Agencourt AMPure XP magnetic beads (Beckman Coulter). Length and quantity of PCR products for sequencing was determined using the Agilent DNA 1000 Kit and the Bioanalyzer 2100 (Agilent).

### High-throughput sequencing and data analysis

190 The barcoded samples were combined to a final concentration of 10 nM DNA and sequenced with the Illumina HiSeq1500 system in paired-end rapid run mode. The libraries were bidirectionally sequenced with read lengths between 120–175 bp in each direction. Raw data were demultiplexed and quality-filtered using web-based tools on the Galaxy platform. Next, all reads were aligned to the matching V $\beta$ , J $\beta$  and C $\beta$  genes, TCR $\beta$  clonotypes  
195 were built from identical sequences, and similar clonotypes were clustered with the MiXCR software (38). TCR clonotype data were further processed using custom scripts in R, in order



to compare samples and characterize specificity and sharing of TCR $\beta$  sequences. Graphs were made with R, GraphPad Prism, or Microsoft Excel. P values were calculated with two-sided Mann-Whitney U tests in GraphPad Prism, version 7.

200

### Identification of specific TCR $\beta$ sequences

Specific TCR $\beta$  clonotypes for each epitope were identified by comparing TCR $\beta$  clonotype frequencies in three samples: one stimulated with the specific peptide of interest (S), one stimulated with a control peptide (C), and unstimulated PBMCs (U). Specific TCR $\beta$  clonotypes were required to be enriched in S over C and in S over U. Let  $s_i$ ,  $c_i$  and  $u_i$  be the relative read frequency (proportion of reads) of clonotype  $i$  in the three samples. To count as specific, clonotypes must exceed two enrichment cut-offs (Supplementary Figure 1, panel B). The first enrichment cut-off was identified as a local minimum of a weighted density distribution of  $\log_{10}(s_i/c_i)$  of all medium- to high-frequency clonotypes, i.e. all clonotypes  $i$  that fulfilled the condition  $s_i c_i > 10^{-6}$ . Analogously, the second enrichment cut-off was identified as a local minimum of a weighted density distribution of  $\log_{10}(s_i/u_i)$  of all clonotypes  $i$  that fulfilled  $s_i u_i > 10^{-7}$ . To eliminate low-fidelity background signals, specific clonotypes must also exceed a specific sample read count cut-off (Supplementary Figure 1, panel C). This cut-off was determined by analyzing the two density distributions of  $\log_{10} s_i$  for all clonotypes  $i$  that had a low frequency in control samples, i. e. an absolute frequency of 1 to 10 reads in samples C or U, respectively. The read count at a local minimum of each of these two distributions was identified, and the mean of these two read counts served as the cut-off value. If any of these two density distributions did not have a local minimum, the cut-off was positioned at its global maximum times 100, i.e. at 100 reads in sample S or higher.

210  
215  
220 Using these criteria, specific TCR $\beta$  clonotypes were identified for 8 CMV-positive donors (P01-P08) and four epitopes (CRV, FRC, RPH, and TPR), resulting in identification of 1052 CMV peptide-specific TCR $\beta$  sequences which were unique at the amino acid level (all specific

sequences are listed in Supplementary Table 2). Identification of antigen-specific TCR $\beta$  sequences from mini-LCL stimulations was achieved in a similar manner by comparing the frequencies of each clonotype in the CMV antigen-stimulated sample to their *ex vivo* frequencies and the frequencies in the samples obtained by stimulation with an empty-vector mini-LCL control. Only TCR $\beta$  sequences that were enriched compared to both control samples were considered specific for epitopes from that CMV antigen.

### 230 **Identification of public and related TCR $\beta$ sequences**

Public CMV epitope-specific TCR $\beta$  sequences and TCR $\beta$  families were identified based on 1052 specific TCR $\beta$  sequences from donors P01–P08. In a first step, TCR $\beta$  sequences were categorized as public if they were CMV-specific in at least two donors with identical V $\beta$  and J $\beta$  gene segments, CDR3 amino acid sequence, and epitope specificity. In a second step, this set of sequences was extended by such TCR $\beta$  sequences that were present in only one donor, but highly similar to public TCR $\beta$  sequences. Sequences were considered highly similar if (a) they used the same V $\beta$  gene segments, (b) had the same CDR3 length, and (c) differed in maximally two amino acids in the CDR3.

## 240 Results

### A method for high-resolution TCR $\beta$ repertoire analysis by peptide stimulation

We devised a method to analyze human epitope-specific TCR $\beta$  repertoires at high resolution. This method combines simple short-term *in vitro* stimulation of peripheral blood mononuclear cells (PBMCs) with synthetic peptide (39, 40) and high-throughput TCR $\beta$  sequencing (Figure 1). Our focus was on donors carrying the HLA class I haplotype B\*07:02~C\*07:02, which is the most frequent HLA-B/C haplotype in donors of European descent (41). We tested the four most immunogenic CMV peptides that are known to be presented by HLA allotypes encoded by this haplotype (17, 19, 42): the HLA-C\*07:02-restricted epitopes CRVLCYV (CRV) and FRCPRRFCF (FRC) and the HLA-B\*07:02-restricted epitopes RPHERNGFTVL (RPH) and TPRVTGGGAM (TPR). HLA-C\*07:02-restricted epitopes are of special clinical interest because their recognition resists viral immunoevasion (17, 18). HLA-C\*07:02 is prevalent not only in people of European descent, but also in East Asian and Native American populations (41).

245 TCR $\beta$  cDNA libraries for Illumina sequencing were prepared from T-cell samples in a 2-step RT-PCR (Figure 1B). The 2-step PCR procedure was designed to limit potential amplification bias due to multiplex priming and to increase fidelity by enabling bidirectional sequencing of the CDR3. After Illumina sequencing, TCR $\beta$  clonotypes were built using the software MiXCR (38). A median of  $5.0 \times 10^6$  productive TCR $\beta$  sequence reads were obtained per sample (Supplementary Table 2). When we plotted TCR $\beta$  clonotype frequencies before and after stimulation, well-separated clusters suggestive of peptide-reactive expanded TCR $\beta$  clonotypes became apparent in CMV-positive, but not in CMV-negative donors (Figure 2). For a more precise definition, we evaluated TCR $\beta$  sequences to be epitope-specific if they appeared in the cluster of enriched clonotypes after cultivation with a specific peptide, but not after cultivation with a control peptide of different HLA restriction (three-sample comparison, enrichment cut-

250

255

260

265

off). In addition, a frequency cut-off was applied to minimize statistical noise from low-frequency clonotypes (Supplementary Figure 1); this cut-off was calculated from the sample-specific clonotype frequency distribution.

We identified a total of 1052 unique TCR $\beta$  amino acid sequences in 8 CMV-positive donors (P01–P08) that met the specificity criteria for exactly one epitope (listed in Supplementary Table 2). Of these, 435 were specific for CRV, 266 for FRC, 191 for RPH, and 160 for TPR. Nineteen TCR $\beta$  sequences passed the criteria for two epitopes, no TCR $\beta$  for more than two epitopes. Thus, we observed minor overlap between TCR $\beta$  sequences assigned to different specificities.

275

### **Peptide stimulation expands T-cell clonotypes that recognize processed antigen**

There is a concern that synthetic peptide may not exclusively stimulate T cells that will be able to recognize the naturally processed epitope (43). Therefore, we tested whether our peptide-enriched T-cell clonotypes respond to endogenously processed CMV antigens. We established autologous mini-lymphoblastoid cell lines (mini-LCLs) that constitutively express CMV proteins pp65 or IE-1 from a mini-Epstein-Barr virus genome. Such mini-LCLs effectively present CMV epitopes of any autologous HLA restriction to CD8<sup>+</sup> and CD4<sup>+</sup> T cells (17, 37, 44, 45). PBMCs of 3 CMV-positive donors, P01-P03, were stimulated with autologous mini-LCLs (pp65, IE-1, or control mini-LCLs without CMV antigen), and the resulting TCR $\beta$  repertoires (Supplementary Table 2) were compared with those obtained through peptide stimulation. In the mini-LCL condition, TCR $\beta$  sequences were considered CMV-specific if they were enriched by stimulation with mini-LCLs that expressed the CMV antigen of interest, but not by stimulation with control mini-LCLs that lacked the CMV antigen. We found that the majority of TCR $\beta$  clonotypes that were expanded by one of the peptides CRV, RPH, or TPR also recognized the corresponding CMV antigen processed by mini-LCLs (Figure 3). These

290

results confirm that our simple peptide stimulation assay is a generally valid approach for the identification of CMV-specific TCR $\beta$  clonotypes of both high and low frequency.

### **CMV-specific TCR $\beta$ clonotypes are abundant in the T-cell repertoire of virus carriers**

295 We investigated the contribution of CMV epitope-specific T-cell receptors to the overall TCR $\beta$  repertoire in peripheral blood of 8 CMV-positive (P01-P08) and 8 CMV-negative (N01-N08) donors. Among the top 100 most frequent *ex vivo* TCR $\beta$  clonotypes of any CMV-positive donor (Figure 4A), 2 to 10 were specific for one of the CMV epitopes CRV, FRC, or TPR. In 7 of 8 CMV-positive donors, CMV-specific clonotypes were among the 5 most frequent clonotypes, 300 and in 2 of 8 donors, they supplied the top-frequency clonotype of the entire repertoire. Among a donor's CMV-specific clonotypes, the most frequent one was specific for CRV in 6 and specific for FRC in 2 of 8 donors. In CMV-negative donors, none of the top 100 TCR $\beta$  clonotypes were specifically enriched by CMV peptide stimulation, and thus none of them was categorized as CMV-specific. When looking at the cumulative read frequencies, 305 CRV- or FRC-specific clonotypes dominated the response in CMV carriers (Figure 4B). These results demonstrate that CMV-specific T cells distinctly shape the T-cell repertoire of virus carriers, with a prominent role for HLA-C-restricted clonotypes.

### **Patterns of V $\beta$ and J $\beta$ gene segment usage in CMV epitope-specific TCRs**

310 We analyzed TCR $\beta$  clonotypes sharing their epitope specificity for shared structural features. First, we evaluated overall use of V $\beta$  and J $\beta$  gene segments (Figure 5) in CMV-specific TCR $\beta$  clonotypes. For each epitope, particular V $\beta$  and J $\beta$  genes were overrepresented, such as V $\beta$ -6-1/-5/-6, V $\beta$ 25-1 and V $\beta$ 28, and J $\beta$ 1-1, J $\beta$ 2-1 or J $\beta$ 2-7 for epitope CRV. However, no V $\beta$ -J $\beta$  combination dominated the response to any of the four epitopes. It follows that gene segment

315 use alone is not sufficiently informative as a marker of CMV-specific CD8<sup>+</sup> T-cell immunity  
to the epitopes studied here.

### **Public CMV-specific TCR $\beta$ sequences and TCR $\beta$ families**

Next, we searched for the presence of identical TCR $\beta$  amino acid sequences with the same  
320 CMV epitope specificity in different donors, known as shared or public TCRs. We found 26  
TCR $\beta$  sequences that were specific in at least 2 out of 8 CMV-positive donors (Table 1). Several  
of these public sequences with the same epitope specificity were closely related in sequence,  
since they used the same V $\beta$  gene, had the same CDR3 length, and differed in a maximum of  
2 amino acids within the CDR3. Hence, we looked for additional TCR $\beta$  sequences that  
325 appeared in only one of the 8 donors, but were closely related to one of the 26 public TCR $\beta$   
sequences according to the criteria stated above; we identified 37 such TCR $\beta$  sequences. The  
resulting set of 63 public or related CMV-specific TCR $\beta$  sequences was composed of 17  
similarity groups, which we refer to as public TCR $\beta$  families. Of the 63 sequences, 21 were  
HLA-B-restricted (epitopes TPR and RPH), and 10 of them had been previously described (29,  
330 42, 46, 47). In contrast, the epitope specificity and HLA restriction of none of the 42 HLA-C-  
restricted TCR $\beta$  sequences (epitopes CRV or FRC) had been previously shown, although 5 of  
these sequences were found to be enriched in CMV-positive donors compared to CMV-  
negative donors (48).

335

**Table 1.** The 63 public or related TCR $\beta$  sequences identified in this study. Only donors are listed in whom the TCRs were functionally identified as epitope-specific. The 26 public TCR $\beta$  sequences are in boldface. Amino acid exchanges in the 37 related TCR $\beta$  sequences compared to the most similar public TCR $\beta$  sequence are highlighted in red.

340

V $\beta$ gene	CDR3 $\beta$ sequence	J $\beta$ gene	Specificity	Donors	Public family	Reference
TRBV25-1	<b>CASSPGDEQFF</b>	TRBJ2-1	CRV	P01, P05, P06, P07	CRV1	(48) <sup>a</sup>
TRBV25-1	<b>CASTPGDEQFF</b>	TRBJ2-1	CRV	P03, P06, P07		(48) <sup>a</sup>
TRBV25-1	CASS <b>A</b> GDEQ <b>Y</b> F	TRBJ2-7	CRV	P05		-
TRBV25-1	CASSPGDEQ <b>Y</b> F	TRBJ2-7	CRV	P01		(48) <sup>a</sup>
TRBV25-1	CASSPGD <b>T</b> Q <b>Y</b> F	TRBJ2-3	CRV	P06		-
TRBV25-1	CAST <b>H</b> GDEQFF	TRBJ2-1	CRV	P05		-
TRBV25-1	CASTPGDEQ <b>Y</b> F	TRBJ2-7	CRV	P06		-
TRBV25-1	CAST <b>Q</b> GDEQFF	TRBJ2-1	CRV	P06		-
TRBV25-1	CAST <b>S</b> GDEQFF	TRBJ2-1	CRV	P07		-
TRBV25-1	CAST <b>T</b> GDEQFF	TRBJ2-1	CRV	P03		-
TRBV25-1	CAT <b>S</b> PGDEQ <b>Y</b> F	TRBJ2-7	CRV	P01		-
TRBV25-1	CAS <b>T</b> L <b>G</b> DEQ <b>Y</b> F	TRBJ2-7	CRV	P05		-
TRBV25-1	CA <b>V</b> T <b>A</b> GDEQFF	TRBJ2-1	CRV	P07		-
TRBV28	<b>CASSPISNEQFF</b>	TRBJ2-1	CRV	P01, P07	CRV2	(48) <sup>a</sup>
TRBV28	<b>CASSPVSNEQFF</b>	TRBJ2-1	CRV	P01, P02		-
TRBV28	CASSPISNEQ <b>Y</b> F	TRBJ2-7	CRV	P01		-
TRBV6-1/6-5/6-6	<b>CASSPGTPRDEQFF</b>	TRBJ2-1	CRV	P03, P05	CRV3	-
TRBV6-1/6-5/6-6	CASS <b>Q</b> GTPRDEQ <b>Y</b> F	TRBJ2-7	CRV	P05		-
TRBV6-1/6-5/6-6	<b>CASSGQKNTEAFF</b>	TRBJ1-1	CRV	P01, P07	CRV4	-
TRBV6-1/6-5/6-6	CASS <b>T</b> GQKNTEAFF	TRBJ1-1	CRV	P01		-
TRBV6-1/6-5/6-6	CAST <b>P</b> GQKNTEAFF	TRBJ1-1	CRV	P04		-
TRBV6-1/6-5/6-6	CAS <b>T</b> T <b>G</b> QKNTEAFF	TRBJ1-1	CRV	P05		-
TRBV6-1/6-5/6-6	CAT <b>T</b> T <b>S</b> GQKNTEAFF	TRBJ1-1	CRV	P01		-
TRBV6-1/6-5/6-6	CAS <b>Q</b> P <b>G</b> QKNTEAFF	TRBJ1-1	CRV	P08		-
TRBV6-1/6-5/6-6	CASS <b>S</b> L <b>T</b> NTTEAFF	TRBJ1-1	CRV	P06		-
TRBV20-1	<b>CSAPDWNNEQFF</b>	TRBJ2-1	CRV	P01, P02	CRV5	-
TRBV20-1	CSAPD <b>W</b> GNEQFF	TRBJ2-1	CRV	P08		-
TRBV20-1	CSAP <b>N</b> WFNEQFF	TRBJ2-1	CRV	P05		-
TRBV20-1	CSAP <b>T</b> WDNEQFF	TRBJ2-1	CRV	P01		-
TRBV28	<b>CASSFPDTQYF</b>	TRBJ2-3	CRV	P01, P02		CRV6
TRBV28	<b>CASTPWGAEAFF</b>	TRBJ1-1	CRV	P04, P08	CRV7	-
TRBV15	<b>CATSRGTGETQYF</b>	TRBJ2-5	FRC	P01, P03, P05	FRC1	-
TRBV15	<b>CATSREGGETQYF</b>	TRBJ2-5	FRC	P05, P06, P08		-
TRBV15	CATS <b>A</b> EGGETQYF	TRBJ2-5	FRC	P08		-
TRBV15	CATS <b>G</b> TAGETQYF	TRBJ2-5	FRC	P08		-
TRBV15	CATSR <b>D</b> AGETQYF	TRBJ2-5	FRC	P06		-
TRBV15	CATSR <b>D</b> GGETQYF	TRBJ2-5	FRC	P02		-
TRBV15	CATSR <b>V</b> AGETQYF	TRBJ2-5	FRC	P06		(48) <sup>a</sup>
TRBV15	CATS <b>V</b> TGETQYF	TRBJ2-5	FRC	P02		-
TRBV6-2/6-3	<b>CASSGGLEAFF</b>	TRBJ1-1	FRC	P03, P07	FRC2	-
TRBV6-2/6-3	CASS <b>L</b> GLEAFF	TRBJ1-1	FRC	P03		-
TRBV4-3	<b>CASSPQRNTEAFF</b>	TRBJ1-1	RPH	P03, P04, P05, P06, P08	RPH1	(46)
TRBV4-3	<b>CASSPARNTEAFF</b>	TRBJ1-1	RPH	P03, P05, P08		(42)
TRBV4-3	<b>CASSPSRNTEAFF</b>	TRBJ1-1	RPH	P03, P08		(42)
TRBV4-3	<b>CASSPHRNTEAFF</b>	TRBJ1-1	RPH	P03, P05		(42)
TRBV4-3	<b>CASSPNRNTEAFF</b>	TRBJ1-1	RPH	P03, P08		(46)
TRBV4-3	CASS <b>P</b> GRNTEAFF	TRBJ1-1	RPH	P03		-
TRBV4-3	CASS <b>P</b> <b>T</b> RNTEAFF	TRBJ1-1	RPH	P08		(46)
TRBV7-8	<b>CASSFRTVSSYEQYF</b>	TRBJ2-7	TPR	P01, P03, P04	TPR1	-
TRBV7-8	<b>CASSFRTVNSYEQYF</b>	TRBJ2-7	TPR	P02, P03		-
TRBV7-8	CASS <b>L</b> RTVSSYEQYF	TRBJ2-7	TPR	P02, P04		-
TRBV7-9	<b>CASSLIGVSSYNEQFF</b>	TRBJ2-1	TPR	P01, P02, P06	TPR2	(29, 42)
TRBV7-9	CASSL <b>K</b> GVSSYNEQFF	TRBJ2-1	TPR	P06		-
TRBV7-9	CASSL <b>R</b> GESSYNEQFF	TRBJ2-1	TPR	P01		-
TRBV7-9	<b>CASSFRQGVNTGELFF</b>	TRBJ2-2	TPR	P01, P02	TPR3	-
TRBV7-9	CASSFRQ <b>S</b> NTGELFF	TRBJ2-2	TPR	P01		-
TRBV7-9	CASSFR <b>S</b> GINTGELFF	TRBJ2-2	TPR	P02		-
TRBV7-9	CASSFRQ <b>T</b> PTGELFF	TRBJ2-2	TPR	P04		-
TRBV6-2/6-3	<b>CASSYSSGELFF</b>	TRBJ2-2	TPR	P01, P08		TPR4
TRBV6-2/6-3	<b>CASSYSGNTEAFF</b>	TRBJ1-1	TPR	P02, P08	TPR5	(47) <sup>a</sup>
TRBV7-2	<b>CASSSRGTVNTEAFF</b>	TRBJ1-1	TPR	P03, P05	TPR6	-
TRBV7-9	<b>CASSLHTQGARTEAFF</b>	TRBJ1-1	TPR	P02, P07	TPR7	-
TRBV7-9	CASSL <b>H</b> <b>S</b> RGARTEAFF	TRBJ1-1	TPR	P02		-

<sup>a</sup> CMV epitope and HLA restriction not described

<sup>b</sup> Reported a different V $\beta$  gene usage

345

### **Public TCR $\beta$ families precisely distinguish CMV-positive from CMV-negative donors**

We analyzed the frequency of public TCR $\beta$  families in primary T cells from an extended cohort of CMV-positive and CMV-negative donors: 8 additional CMV-positive donors (P09-P16) and 9 CMV-negative donors (N01-N09) with the HLA-B\*07:02~C\*07:02 haplotype. Public TCR $\beta$  family members were much more abundant in CMV-positive than CMV-negative donors (Figure 6A). This was true for each of the four CMV epitopes when evaluated separately (Figure 6B, left). Taking all epitopes together, the median cumulative read frequency was 171-fold higher in CMV-positive than in CMV-negative donors of our 25-donor cohort (Figure 6C; data for each TCR $\beta$  and donor are provided in Supplementary Table 3). Mean cumulative frequency in donors P09-P16 and donors P01-P08 was similar, which showed that there was no bias in favor of the P01-P08 cohort of donors in whom the sequences were originally identified. To further validate the set of public TCR $\beta$  families, we tested it on a larger cohort of donors whose *ex vivo* TCR $\beta$  repertoires were recently published (48) and whose CMV status and partial HLA type (low resolution HLA-A and -B, no HLA-C) was available. Since presence of HLA-B7 is a strong indicator of the presence of the haplotype HLA-B\*07:02~C\*07:02 in persons of European descent, whereas persons of Asian descent often express HLA-C\*07:02 without HLA-B\*07:02 (41), we limited our analysis to the 352 donors categorized as “White, not Hispanic or Latino”. Of these donors, 94 were HLA-B7-positive, and 258 were HLA-B7-negative. As shown in Figure 6C, CMV-specific public TCR $\beta$  families were strongly enriched in HLA-B7-positive, CMV-positive donors, but not in HLA-B7-positive, CMV-negative donors ( $P < 1 \times 10^{-15}$ ). In HLA-B7-negative donors, no enrichment was observed irrespective of CMV status. In a separate analysis of each epitope in this cohort, CRV was the strongest discriminator ( $P = 7.5 \times 10^{-13}$ ; Figure 6B, right).

350

355

360

365



A chosen cut-off value of  $10^{-4}$  for the total proportion of reads of our set of 63 public or related  
370 TCR $\beta$  sequences lead to perfect discrimination between CMV-positive and CMV-negative  
donors within our cohort, and very good identification of CMV-positive donors within the  
HLA-B7-positive published cohort (F1 score = 0.93; 100% specificity, 88% sensitivity). Taken  
together, our results show that the CMV-specific TCR $\beta$  signature, as identified through our  
approach, is highly indicative of CMV-specific T-cell immunity associated with the CMV  
375 status in healthy donors.

## Discussion

380 Here we analyzed the composition and sharing of TCR $\beta$  repertoires against four epitopes that are major targets of the CMV-specific CD8<sup>+</sup> T-cell response. Specific TCRs against two of these epitopes, restricted through HLA-C, had not been studied before. We identified a set of CMV-specific public TCR $\beta$  families that distinguishes CMV-positive from CMV-negative healthy persons in two independent cohorts with high precision.

385 We show that the CMV epitopes studied here considerably shape the T-cell repertoire of healthy virus carriers. HLA-C\*07:02-restricted T cells were particularly prominent; in 6 of 8 donors they provided one of the four most frequent TCR $\beta$  clonotypes to the overall T-cell repertoire, and in 2 of these donors the top-frequency TCR $\beta$  clonotype. These results expand on the general observation that CMV-specific T cells make up for a large proportion of the CD8<sup>+</sup> T-cell repertoire, on average amounting to 5% of the total CD8<sup>+</sup> T-cell response based on interferon- $\gamma$  secretion (49). This proportion is likely to be even larger when all antigen-specific cells are included in measurements, not just those that exert a chosen effector function at the time of analysis (50). Advanced donor age boosts CMV-specific T-cell frequencies as well (19), an aspect we could not investigate in our cohort of anonymous donors.

395 The TCR $\beta$  signatures of the CMV epitope-specific T cells studied here were diverse. For a given epitope, the dominant TCR $\beta$  sequence was usually a different one in different donors. Thus, TCR $\beta$  repertoires were not dominated across the board by heavily conserved (public) sequences, in contrast to what was observed for some epitopes from influenza (51, 52) or EBV (53). Rather, the TCR $\beta$  repertoires studied here were mostly composed of clonotypes that were shared with only a subset of matched donors, or were entirely donor-specific (private). These patterns are reminiscent of those previously found for TCR repertoires of HLA-A- and HLA-B-restricted CMV-specific T cells (29–31, 33, 34, 54, 55). Nonetheless, our approach identified a series of public TCR $\beta$  chains whose cumulative frequency was strongly indicative of CMV

400

carrier status in larger cohorts of healthy donors, even though these public TCRs did not  
405 necessarily represent the most abundant epitope-specific T cells in the 8 donors in whom they  
were originally identified. It seems clear that exclusive TCR $\beta$  sequencing underestimates the  
true diversity of an epitope-specific T-cell response, since the same TCR $\beta$  can be paired with  
different TCR $\alpha$  chains to generate the same or an overlapping human antiviral epitope  
specificity (53, 56, 57). However, our results show that TCR $\beta$  sequencing, even in the absence  
410 of TCR $\alpha$  analysis, is already highly informative regarding the CMV-specific T-cell status of  
donors. This finding may already have been anticipated by a recent large-scale study (48),  
which showed that signatures of enriched TCR $\beta$  sequences distinguished CMV-positive from  
CMV-negative donors with high precision. Our study extends these findings by demonstrating  
the predictive power of TCR $\beta$  sequences with known CMV epitope specificity. In contrast, the  
415 previous study (48) analyzed TCR $\beta$  sequences that were CMV-associated, but mostly not  
known to be CMV-specific, which means that other pathogens with overlapping epidemiology  
may have contributed to the signal. For future diagnostic or prognostic applications in  
immunocompromised patients, it will be preferable to focus on analysis of precisely defined  
antigen-specific TCR $\beta$ s, since such patients may simultaneously reactivate or acquire multiple,  
420 and even related, pathogens. We conclude that TCR $\beta$  sequencing provides a highly informative  
and economic standalone approach to identification of epitope-specific T cells in healthy  
carriers and patients at risk of viral reactivation and in potential need of antiviral prophylaxis  
or treatment (1, 58, 59).

Conserved TCR $\beta$  chains are not necessarily perfectly conserved. It was often observed that  
425 human HLA-A- or HLA-B-restricted CD8<sup>+</sup> T-cell responses to an epitope contain non-  
identical but highly similar TCR $\beta$  chains; these use the same or closely related V $\beta$  and J $\beta$   
segments and typically have CDR3 regions that show exchanges in only few amino acid  
positions. Such relationships are apparent in datasets on multiple epitopes from CMV (29, 31,  
42, 55, 60, 61), EBV (29, 31, 53, 61–64), HIV (29), or influenza virus (51, 52). Similarity

430 between TCR $\beta$  chains of the same specificity can also manifest as the presence of conserved  
short motifs within the CDR3 (29, 52), often at or near residues 6 and 7; these residues are at  
its center and generally make strong contributions to binding of MHC/peptide by the TCR and  
shaping T-cell specificity (65). Analysis of such TCR $\beta$  relationships was recently taken to a  
more comprehensive level (33, 34) by the design of computational algorithms to cluster T cells  
435 of the same specificity according to multiple indicators of sequence similarity. Global sequence  
similarity of the CDR3 is the single factor that predicts specificity best (34), and prediction is  
further improved by adding aspects such as CDR3 length and V $\beta$  gene segment usage.  
Accordingly, we observed multiple occurrences of high similarity of CDR3 sequence, length  
and V $\beta$  usage among our 26 CMV-specific public TCRs. Therefore, we decided to group CMV-  
440 specific public and related TCR $\beta$ s into families based on these criteria. We found that TCR $\beta$   
families that were defined in this way could precisely distinguish healthy persons with and  
without established CMV-specific T-cell immunity. Public TCR $\beta$  family sequences were as  
rare in CMV-negative persons who carry the relevant HLA haplotype as in CMV-positive  
persons who lack the HLA haplotype. This finding shows that such TCR $\beta$  family members are  
445 unlikely to appear in T cells of irrelevant specificity or HLA restriction, confirms the predictive  
power of TCR $\beta$  sequencing, and suggests that our TCR $\beta$  grouping approach can in future  
studies be extended to a broader variety of epitopes, viruses, or antigenic entities.

Since its initial description (26, 32), high-throughput sequencing of TCR $\beta$  repertoires has  
become a widely used research method, but it has not yet found wide clinical application. We  
450 have now introduced technical improvements that will enhance its robustness and applicability  
to accelerate advancement to routine clinical use. Dual-indexed, paired-end bidirectional  
sequencing of the entire CDR3 region is likely to reduce errors in the resulting Illumina  
sequencing data (66). Our technique to identify epitope-specific TCR $\beta$  repertoires by peptide  
stimulation and comparison to two controls eliminates the need to physically isolate specific  
455 T cells. Earlier studies that aimed at characterizing epitope-specific TCR repertoires have

generally employed sorting of HLA/peptide multimer-labeled T cells (33–35, 54, 61), or occasionally sorting of T cells labeled with markers of activation or proliferation (67). High-throughput sequencing has the capacity to identify TCR sequences even from very low-frequency components of the sample. However, T-cell subsets sorted based on multimers or other markers are not perfectly pure, and there is a possibility that low-frequency contaminants, which may derive from dominant clones from the parent population, are erroneously assigned the specificity of interest. Regardless whether multimer sorting or peptide stimulation is used to identify specific TCR clonotypes, artifacts can be avoided by quantitatively verifying enrichment of clonotypes relative to the parent population and relative to a sample treated with a different multimer or peptide. Our present approach has the limitation that it only covers T cells capable of proliferating *in vitro* in response to antigen. However, depending on the research question at hand, this limitation may be advantageous, since T cells capable of proliferation will in many cases be those that are functionally more relevant in disease or immune control. Moreover, the numerical increase of antigen-responsive T cells due to proliferation, as well as the increased absolute amount of TCR $\beta$  mRNA per cell several days after activation (68), will in itself increase resolution and thus the likelihood that rare clonotypes can be detected in samples of limited size. In contrast, HLA/peptide multimer staining can capture T cells that express a specific TCR irrespective of their functional properties; however, in spite of recent progress (69, 70), multimers are still challenging to produce for certain HLA allotypes and epitopes, and they may not always stain the entire antigen-specific T-cell population (71).

It seems safe to predict that identification and quantification of antigen-specific TCR $\beta$  repertoires will increasingly enter clinical practice for purposes of diagnostics and monitoring. Repositories of annotated antigen-specific TCRs (72), refined computational tools for TCR sequence analysis (38) and TCR sequence datasets (48), generously made available to the public, will be of great use in further developing the method. With growing datasets, an

increasing number of epitope-specific TCR sequences against various pathogens will be found to be shared between carriers. Such public TCR sequences will find application in various fields. In clinical research, public TCR sequences may be used as indicators to track virus-specific T-cell responses in patients after transplantation in order to identify epitopes that mobilize a protective T-cell response against pathogens such as CMV (6). Virus-specific TCR signatures may also be exploited in diagnostics and disease monitoring (36, 73, 74) to inform about a patient's status regarding past or present infection with multiple pathogens, success of vaccination or T-cell transfer, and risk of future infection or reactivation. Pathogen-specific TCRs that are frequently present in the self-tolerant repertoire of multiple healthy donors are likely to be non-responsive to human antigens in various genetic backgrounds. Such TCRs carry a low risk of allo-HLA cross-reactivity (75) and are therefore favorable candidates for immunotherapy with TCR-transgenic T cells (76).

495

## References

- 500 1. Cwynarski, K., J. Ainsworth, M. Cobbold, S. Wagner, P. Mahendra, J. Apperley, J. Goldman, C. Craddock, and P. A. Moss. 2001. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. *Blood* 97: 1232-1240.
- 505 2. Hebart, H., S. Deginik, S. Stevanovic, U. Grigoleit, A. Dobler, M. Baur, G. Rauser, C. Sinzger, G. Jahn, J. Loeffler, L. Kanz, H. G. Rammensee, and H. Einsele. 2002. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. *Blood* 99: 3830-3837.
- 510 3. Boeckh, M. 2011. Complications, diagnosis, management, and prevention of CMV infections: current and future. *Hematology Am Soc Hematol Educ Program* 2011: 305-309.
- 515 4. Chemaly, R. F., S. Chou, H. Einsele, P. Griffiths, R. Avery, R. R. Razonable, K. M. Mullane, C. Kotton, J. Lundgren, T. E. Komatsu, P. Lischka, F. Josephson, C. M. Douglas, O. Umeh, V. Miller, P. Ljungman, and D. W. G. O. T. C. D. D. F. Resistant. 2018. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. *Clin Infect Dis* doi: 10.1093/cid/ciy696:
- 520 5. Roddie, C., and K. S. Peggs. 2017. Immunotherapy for transplantation-associated viral infections. *J Clin Invest* 127: 2513-2522.
6. van der Heiden, P., E. Marijt, F. Falkenburg, and I. Jedema. 2018. Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution. *Biol Blood Marrow Transplant* 24: 1776-1782.
7. Crough, T., and R. Khanna. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. *Clin Microbiol Rev* 22: 76-98, Table of Contents.
- 525 8. Halenius, A., C. Gerke, and H. Hengel. 2015. Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver. *Cell Mol Immunol* 12: 139-153.
9. Noriega, V., V. Redmann, T. Gardner, and D. Tortorella. 2012. Diverse immune evasion strategies by human cytomegalovirus. *Immunol Res* 54: 140-151.
- 530 10. Smith, C., S. Gras, R. M. Brennan, N. L. Bird, S. A. Valkenburg, K. A. Twist, J. M. Burrows, J. J. Miles, D. Chambers, S. Bell, S. Campbell, K. Kedzierska, S. R. Burrows, J. Rossjohn, and R. Khanna. 2014. Molecular imprint of exposure to naturally occurring genetic variants of human cytomegalovirus on the T cell repertoire. *Sci Rep* 4: 3993.
- 535 11. Kern, F., I. P. Surel, N. Faulhaber, C. Frömmel, J. Schneider-Mergener, C. Schönemann, P. Reinke, and H. D. Volk. 1999. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. *J Virol* 73: 8179-8184.
- 540 12. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. *J Virol* 70: 7569-7579.
13. Manley, T. J., L. Luy, T. Jones, M. Boeckh, H. Mutimer, and S. R. Riddell. 2004. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. *Blood* 104: 1075-1082.
- 545 14. Bunde, T., A. Kirchner, B. Hoffmeister, D. Habedank, R. Hetzer, G. Cherepnev, S. Proesch, P. Reinke, H. D. Volk, H. Lehmkuhl, and F. Kern. 2005. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. *J Exp Med* 201: 1031-1036.

15. Sacre, K., S. Nguyen, C. Deback, G. Carcelain, J. P. Vernant, V. Leblond, B. Autran, and N. Dhedin. 2008. Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8<sup>+</sup> T cells and control of HCMV replication after allogeneic stem cell transplantation. *J Virol* 82: 10143-10152.
16. Reddehase, M. J., W. Mutter, K. Münch, H. J. Bühring, and U. H. Koszinowski. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. *J Virol* 61: 3102-3108.
17. Ameres, S., J. Mautner, F. Schlott, M. Neuenhahn, D. H. Busch, B. Plachter, and A. Moosmann. 2013. Presentation of an immunodominant immediate-early CD8<sup>+</sup> T cell epitope resists human cytomegalovirus immunoevasion. *PLoS Pathog* 9: e1003383.
18. Ameres, S., K. Besold, B. Plachter, and A. Moosmann. 2014. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. *J Immunol* 192: 5894-5905.
19. Hosie, L., A. Pachnio, J. Zuo, H. Pearce, S. Riddell, and P. Moss. 2017. Cytomegalovirus-Specific T Cells Restricted by HLA-Cw\*0702 Increase Markedly with Age and Dominate the CD8<sup>+</sup> T-Cell Repertoire in Older People. *Front Immunol* 8: 1776.
20. Kim, S., S. Lee, J. Shin, Y. Kim, I. Evnouchidou, D. Kim, Y. K. Kim, Y. E. Kim, J. H. Ahn, S. R. Riddell, E. Stratikos, V. N. Kim, and K. Ahn. 2011. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. *Nat Immunol* 12: 984-991.
21. Padovan, E., G. Casorati, P. Dellabona, S. Meyer, M. Brockhaus, and A. Lanzavecchia. 1993. Expression of two T cell receptor alpha chains: dual receptor T cells. *Science* 262: 422-424.
22. Davis, M. M., and P. J. Bjorkman. 1988. T-cell antigen receptor genes and T-cell recognition. *Nature* 334: 395-402.
23. Mackelprang, R., C. S. Carlson, L. Subrahmanyam, R. J. Livingston, M. A. Eberle, and D. A. Nickerson. 2002. Sequence variation in the human T-cell receptor loci. *Immunol Rev* 190: 26-39.
24. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. *Nature* 384: 134-141.
25. Arstila, T. P., A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, and P. Kourilsky. 1999. A direct estimate of the human alphabeta T cell receptor diversity. *Science* 286: 958-961.
26. Robins, H. S., P. V. Campregher, S. K. Srivastava, A. Wachter, C. J. Turtle, O. Khasai, S. R. Riddell, E. H. Warren, and C. S. Carlson. 2009. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. *Blood* 114: 4099-4107.
27. Robins, H. S., S. K. Srivastava, P. V. Campregher, C. J. Turtle, J. Andriesen, S. R. Riddell, C. S. Carlson, and E. H. Warren. 2010. Overlap and effective size of the human CD8<sup>+</sup> T cell receptor repertoire. *Sci Transl Med* 2: 47ra64.
28. Qi, Q., Y. Liu, Y. Cheng, J. Glanville, D. Zhang, J. Y. Lee, R. A. Olshen, C. M. Weyand, S. D. Boyd, and J. J. Goronzy. 2014. Diversity and clonal selection in the human T-cell repertoire. *Proc Natl Acad Sci U S A* 111: 13139-13144.
29. Miconnet, I., A. Marrau, A. Farina, P. Taffé, S. Vigano, A. Harari, and G. Pantaleo. 2011. Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure. *J Immunol* 186: 7039-7049.
30. Price, D. A., J. M. Brenchley, L. E. Ruff, M. R. Betts, B. J. Hill, M. Roederer, R. A. Koup, S. A. Migueles, E. Gostick, L. Wooldridge, A. K. Sewell, M. Connors, and D. C. Douek. 2005. Avidity for antigen shapes clonal dominance in CD8<sup>+</sup> T cell populations specific for persistent DNA viruses. *J Exp Med* 202: 1349-1361.




31. Venturi, V., H. Y. Chin, T. E. Asher, K. Ladell, P. Scheinberg, E. Bornstein, D. van  
600 Bockel, A. D. Kelleher, D. C. Douek, D. A. Price, and M. P. Davenport. 2008. TCR  
beta-chain sharing in human CD8<sup>+</sup> T cell responses to cytomegalovirus and EBV. *J  
Immunol* 181: 7853-7862.
32. Freeman, J. D., R. L. Warren, J. R. Webb, B. H. Nelson, and R. A. Holt. 2009. Profiling  
605 the T-cell receptor beta-chain repertoire by massively parallel sequencing. *Genome Res*  
19: 1817-1824.
33. Dash, P., A. J. Fiore-Gartland, T. Hertz, G. C. Wang, S. Sharma, A. Souquette, J. C.  
Crawford, E. B. Clemens, T. H. O. Nguyen, K. Kedzierska, N. L. La Gruta, P. Bradley,  
and P. G. Thomas. 2017. Quantifiable predictive features define epitope-specific T cell  
receptor repertoires. *Nature* 547: 89-93.
- 610 34. Glanville, J., H. Huang, A. Nau, O. Hatton, L. E. Wagar, F. Rubelt, X. Ji, A. Han, S. M.  
Krams, C. Pettus, N. Haas, C. S. L. Arlehamn, A. Sette, S. D. Boyd, T. J. Scriba, O. M.  
Martinez, and M. M. Davis. 2017. Identifying specificity groups in the T cell receptor  
repertoire. *Nature* 547: 94-98.
- 615 35. Klarenbeek, P. L., E. B. Remmerswaal, I. J. ten Berge, M. E. Doorenspleet, B. D. van  
Schaik, R. E. Esveldt, S. D. Koch, A. ten Brinke, A. H. van Kampen, F. J. Bemelman, P.  
P. Tak, F. Baas, N. de Vries, and R. A. van Lier. 2012. Deep sequencing of antiviral T-  
cell responses to HCMV and EBV in humans reveals a stable repertoire that is  
maintained for many years. *PLoS Pathog* 8: e1002889.
- 620 36. Suessmuth, Y., R. Mukherjee, B. Watkins, D. T. Koura, K. Finstermeier, C. Desmarais,  
L. Stempora, J. T. Horan, A. Langston, M. Qayed, H. J. Houry, A. Grizzle, J. A.  
Cheeseman, J. A. Conger, J. Robertson, A. Garrett, A. D. Kirk, E. K. Waller, B. R.  
Blazar, A. K. Mehta, H. S. Robins, and L. S. Kean. 2015. CMV reactivation drives  
posttransplant T-cell reconstitution and results in defects in the underlying TCRβ  
repertoire. *Blood* 125: 3835-3850.
- 625 37. Moosmann, A., N. Khan, M. Cobbold, C. Zentz, H. J. Delecluse, G. Hollweck, A. D.  
Hislop, N. W. Blake, D. Croom-Carter, B. Wollenberg, P. A. Moss, R. Zeidler, A. B.  
Rickinson, and W. Hammerschmidt. 2002. B cells immortalized by a mini-Epstein-Barr  
virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. *Blood*  
100: 1755-1764.
- 630 38. Bolotin, D. A., S. Poslavsky, I. Mitrophanov, M. Shugay, I. Z. Mamedov, E. V.  
Putintseva, and D. M. Chudakov. 2015. MiXCR: software for comprehensive adaptive  
immunity profiling. *Nat Methods* 12: 380-381.
- 635 39. Gary, R., M. Aigner, S. Moi, S. Schaffer, A. Gottmann, S. Maas, R. Zimmermann, J.  
Zingsem, J. Strobel, A. Mackensen, J. Mautner, A. Moosmann, and A. Gerbitz. 2018.  
Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF  
mobilized stem cell grafts. *J Transl Med* 16: 124.
- 640 40. Gerdemann, U., J. M. Keirnan, U. L. Katari, R. Yanagisawa, A. S. Christin, L. E. Huye,  
S. K. Perna, S. Ennamuri, S. Gottschalk, M. K. Brenner, H. E. Heslop, C. M. Rooney,  
and A. M. Leen. 2012. Rapidly generated multivirus-specific cytotoxic T lymphocytes  
for the prophylaxis and treatment of viral infections. *Mol Ther* 20: 1622-1632.
41. Gragert, L., A. Madbouly, J. Freeman, and M. Maiers. 2013. Six-locus high resolution  
HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire  
US donor registry. *Hum Immunol* 74: 1313-1320.
- 645 42. Weekes, M. P., M. R. Wills, K. Mynard, A. J. Carmichael, and J. G. Sissons. 1999. The  
memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection  
contains individual peptide-specific CTL clones that have undergone extensive  
expansion in vivo. *J Virol* 73: 2099-2108.
43. Yewdell, J. W. 2005. The seven dirty little secrets of major histocompatibility complex  
class I antigen processing. *Immunol Rev* 207: 8-18.

- 650 44. Ameres, S., X. Liang, M. Wiesner, J. Mautner, and A. Moosmann. 2015. A Diverse  
Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human  
Cytomegalovirus. *Front Immunol* 6: 598.
45. Wiesner, M., C. Zentz, M. H. Hammer, M. Cobbold, F. Kern, H. J. Kolb, W.  
Hammerschmidt, R. Zeidler, and A. Moosmann. 2005. Selection of CMV-specific  
655 CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. *Eur J Immunol* 35:  
2110-2121.
46. Brennan, R. M., J. Petersen, M. A. Neller, J. J. Miles, J. M. Burrows, C. Smith, J.  
McCluskey, R. Khanna, J. Rossjohn, and S. R. Burrows. 2012. The impact of a large  
and frequent deletion in the human TCR  $\beta$  locus on antiviral immunity. *J Immunol* 188:  
660 2742-2748.
47. Dziubianau, M., J. Hecht, L. Kuchenbecker, A. Sattler, U. Stervbo, C. Rödelsperger, P.  
Nickel, A. U. Neumann, P. N. Robinson, S. Mundlos, H. D. Volk, A. Thiel, P. Reinke,  
and N. Babel. 2013. TCR repertoire analysis by next generation sequencing allows  
complex differential diagnosis of T cell-related pathology. *Am J Transplant* 13: 2842-  
665 2854.
48. Emerson, R. O., W. S. DeWitt, M. Vignali, J. Gravley, J. K. Hu, E. J. Osborne, C.  
Desmarais, M. Klinger, C. S. Carlson, J. A. Hansen, M. Rieder, and H. S. Robins. 2017.  
Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-  
mediated effects on the T cell repertoire. *Nat Genet* 49: 659-665.
- 670 49. Sylwester, A. W., B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R.  
Sleath, K. H. Grabstein, N. A. Hosken, F. Kern, J. A. Nelson, and L. J. Picker. 2005.  
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the  
memory compartments of exposed subjects. *J Exp Med* 202: 673-685.
50. Tan, L. C., N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O'Callaghan, S. Rowland-  
675 Jones, A. J. McMichael, A. B. Rickinson, and M. F. Callan. 1999. A re-evaluation of the  
frequency of CD8+ T cells specific for EBV in healthy virus carriers. *J Immunol* 162:  
1827-1835.
51. Chen, G., X. Yang, A. Ko, X. Sun, M. Gao, Y. Zhang, A. Shi, R. A. Mariuzza, and N. P.  
Weng. 2017. Sequence and Structural Analyses Reveal Distinct and Highly Diverse  
680 Human CD8+ TCR Repertoires to Immunodominant Viral Antigens. *Cell Rep* 19: 569-  
583.
52. Lehner, P. J., E. C. Wang, P. A. Moss, S. Williams, K. Platt, S. M. Friedman, J. I. Bell,  
and L. K. Borysiewicz. 1995. Human HLA-A0201-restricted cytotoxic T lymphocyte  
recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment.  
685 *J Exp Med* 181: 79-91.
53. Miles, J. J., N. A. Borg, R. M. Brennan, F. E. Tynan, L. Kjer-Nielsen, S. L. Silins, M. J.  
Bell, J. M. Burrows, J. McCluskey, J. Rossjohn, and S. R. Burrows. 2006. TCR alpha  
genes direct MHC restriction in the potent human T cell response to a class I-bound  
viral epitope. *J Immunol* 177: 6804-6814.
- 690 54. Klinger, M., F. Pepin, J. Wilkins, T. Asbury, T. Wittkop, J. Zheng, M. Moorhead, and  
M. Faham. 2015. Multiplex Identification of Antigen-Specific T Cell Receptors Using a  
Combination of Immune Assays and Immune Receptor Sequencing. *PLoS One* 10:  
e0141561.
55. Trautmann, L., M. Rimbart, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V.  
695 Cerundolo, and M. Bonneville. 2005. Selection of T cell clones expressing high-affinity  
public TCRs within Human cytomegalovirus-specific CD8 T cell responses. *J Immunol*  
175: 6123-6132.
56. Dong, L., P. Li, T. Oenema, C. L. McClurkan, and D. M. Koelle. 2010. Public TCR use  
by herpes simplex virus-2-specific human CD8 CTLs. *J Immunol* 184: 3063-3071.


- 700 57. Misko, I. S., S. M. Cross, R. Khanna, S. L. Elliott, C. Schmidt, S. J. Pye, and S. L. Silins. 1999. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. *Proc Natl Acad Sci U S A* 96: 2279-2284.
58. Gratama, J. W., J. W. van Esser, C. H. Lamers, C. Tournay, B. Löwenberg, R. L. Bolhuis, and J. J. Cornelissen. 2001. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8<sup>+</sup> T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. *Blood* 98: 1358-1364.
- 705 59. Wagner, H. J., Y. C. Cheng, M. H. Huls, A. P. Gee, I. Kuehnle, R. A. Krance, M. K. Brenner, C. M. Rooney, and H. E. Heslop. 2004. Prompt versus preemptive intervention for EBV lymphoproliferative disease. *Blood* 103: 3979-3981.
- 710 60. Iancu, E. M., P. Corthesy, P. Baumgaertner, E. Devevre, V. Voelter, P. Romero, D. E. Speiser, and N. Rufer. 2009. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. *J Immunol* 183: 319-331.
- 715 61. Koning, D., A. I. Costa, I. Hoof, J. J. Miles, N. M. Nanlohy, K. Ladell, K. K. Matthews, V. Venturi, I. M. Schellens, J. A. Borghans, C. Kesmir, D. A. Price, and D. van Baarle. 2013. CD8<sup>+</sup> TCR repertoire formation is guided primarily by the peptide component of the antigenic complex. *J Immunol* 190: 931-939.
- 720 62. Fazou, C., H. Yang, A. J. McMichael, and M. F. Callan. 2001. Epitope specificity of clonally expanded populations of CD8<sup>+</sup> T cells found within the joints of patients with inflammatory arthritis. *Arthritis Rheum* 44: 2038-2045.
63. Lim, A., L. Trautmann, M. A. Peyrat, C. Couedel, F. Davodeau, F. Romagné, P. Kourilsky, and M. Bonneville. 2000. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. *J Immunol* 165: 2001-2011.
- 725 64. Miles, J. J., D. Elhassen, N. A. Borg, S. L. Silins, F. E. Tynan, J. M. Burrows, A. W. Purcell, L. Kjer-Nielsen, J. Rossjohn, S. R. Burrows, and J. McCluskey. 2005. CTL recognition of a bulged viral peptide involves biased TCR selection. *J Immunol* 175: 3826-3834.
- 730 65. Stadinski, B. D., K. Shekhar, I. Gómez-Touriño, J. Jung, K. Sasaki, A. K. Sewell, M. Peakman, A. K. Chakraborty, and E. S. Huseby. 2016. Hydrophobic CDR3 residues promote the development of self-reactive T cells. *Nat Immunol* 17: 946-955.
- 735 66. Kozich, J. J., S. L. Westcott, N. T. Baxter, S. K. Highlander, and P. D. Schloss. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol* 79: 5112-5120.
67. Klinger, M., K. Kong, M. Moorhead, L. Weng, J. Zheng, and M. Faham. 2013. Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells. *PLoS One* 8: e74231.
- 740 68. Paillard, F., G. Sterkers, and C. Vaquero. 1990. Transcriptional and post-transcriptional regulation of TcR, CD4 and CD8 gene expression during activation of normal human T lymphocytes. *EMBO J* 9: 1867-1872.
- 745 69. Braendstrup, P., S. Justesen, T. Osterbye, L. L. Nielsen, R. Mallone, L. Vindeløv, A. Stryhn, and S. Buus. 2013. MHC class II tetramers made from isolated recombinant  $\alpha$  and  $\beta$  chains refolded with affinity-tagged peptides. *PLoS One* 8: e73648.
70. Schlott, F., D. Steubl, S. Ameres, A. Moosmann, S. Dreher, U. Heemann, V. Hösel, D. H. Busch, and M. Neuenhahn. 2018. Characterization and clinical enrichment of HLA-C\*07:02-restricted Cytomegalovirus-specific CD8<sup>+</sup> T cells. *PLoS One* 13: e0193554.
- 750

71. Rius, C., M. Attaf, K. Tungatt, V. Bianchi, M. Legut, A. Bovay, M. Donia, P. Thor Straten, M. Peakman, I. M. Svane, S. Ott, T. Connor, B. Szomolay, G. Dolton, and A. K. Sewell. 2018. Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. *J Immunol* 200: 2263-2279.  
755
72. Shugay, M., D. V. Bagaev, I. V. Zvyagin, R. M. Vroomans, J. C. Crawford, G. Dolton, E. A. Komech, A. L. Sycheva, A. E. Koneva, E. S. Egorov, A. V. Eliseev, E. Van Dyk, P. Dash, M. Attaf, C. Rius, K. Ladell, J. E. McLaren, K. K. Matthews, E. B. Clemens, D. C. Douek, F. Luciani, D. van Baarle, K. Kedzierska, C. Kesmir, P. G. Thomas, D. A. Price, A. K. Sewell, and D. M. Chudakov. 2018. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. *Nucleic Acids Res* 46: D419-D427.  
760
73. Nguyen, T. H., N. L. Bird, E. J. Grant, J. J. Miles, P. G. Thomas, T. C. Kotsimbos, N. A. Mifsud, and K. Kedzierska. 2017. Maintenance of the EBV-specific CD8<sup>+</sup> TCRαβ repertoire in immunosuppressed lung transplant recipients. *Immunol Cell Biol* 95: 77-86.  
765
74. van Heijst, J. W., I. Ceberio, L. B. Lipuma, D. W. Samilo, G. D. Wasilewski, A. M. Gonzales, J. L. Nieves, M. R. van den Brink, M. A. Perales, and E. G. Pamer. 2013. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. *Nat Med* 19: 372-377.  
770
75. Amir, A. L., L. J. D'Orsogna, D. L. Roelen, M. M. van Loenen, R. S. Hagedoorn, R. de Boer, M. A. van der Hoorn, M. G. Kester, I. I. Doxiadis, J. H. Falkenburg, F. H. Claas, and M. H. Heemskerk. 2010. Allo-HLA reactivity of virus-specific memory T cells is common. *Blood* 115: 3146-3157.
76. Schub, A., I. G. Schuster, W. Hammerschmidt, and A. Moosmann. 2009. CMV-specific TCR-transgenic T cells for immunotherapy. *J Immunol* 183: 6819-6830.  
775



**Figure 1. Experimental setup.** (A) Schema of the three-sample assay used to expand and analyze peptide-specific T cells. PBMCs were isolated from peripheral blood of healthy donors, loaded with single CMV-derived peptides, and cultured for 10 days with IL-2. Cells before and after stimulation were lysed, and TCR $\beta$  libraries were prepared from bulk RNA and analyzed by high-throughput sequencing. Specific TCR $\beta$  sequences for each epitope were identified by comparing TCR $\beta$  clonotype frequencies in three samples, (i) stimulated with specific peptide, (ii) stimulated with control peptide, and (iii) before stimulation. Clonotypes that were enriched in condition (i), but not in controls (ii) and (iii), were considered specific. (B) Preparation of TCR $\beta$  libraries for bidirectional sequencing of the CDR3. After total RNA isolation, TCR $\beta$

RNA was reversely transcribed using a C $\beta$  gene-specific primer. In a first PCR step, cDNA was amplified by semi-multiplexed PCR with a mix of 42 forward primers that covered all V $\beta$  genes and appended the Illumina sequencing read 2 primer binding site to the product, and a reverse primer that was complementary to both C $\beta$  genes and appended the sequencing read 1 priming site. A second PCR step was performed with a single primer on each side which adds Illumina i5 and i7 adapters and sample indices for multiplexing.




795

**Figure 2. Populations of enriched TCR $\beta$  clonotypes are exclusive to CMV positive donors.**


Relative frequency (proportion of reads) of TCR $\beta$  clonotypes before (x-axis) and after (y-axis) stimulation with one of four CMV peptides in CMV-positive donor P01 (upper panel) and  
800 CMV-negative donor N05 (lower panel). Each TCR $\beta$  clonotype is defined as the entirety of identical reads on the nucleotide level and represented by a black dot. Clonotypes that were undetectable in one condition were assigned a pseudofrequency corresponding to 0.5 reads to enable their display on a logarithmic axis.

805



**Figure 3. Specific TCRβ clonotypes identified in the peptide stimulation assay also respond to endogenously processed antigen.** The analysis was performed for the IE-1 antigen (epitope CRV) in CMV-positive donors P01, P02, and P03, and for the pp65 antigen (epitopes RPH and TPR) in donors P01 and P03. The plot shows all TCRβ clonotypes that were identified as epitope-specific in the peptide stimulation assay. The y-axis indicates the frequency of each clonotype after peptide stimulation. Colored dots represent clonotypes that were specifically enriched by stimulation with an autologous mini-LCL that expresses the corresponding CMV antigen, grey dots indicate clonotypes for which this was not the case. The numbers on top indicate the total number of epitope-specific TCRβ clonotypes and, in parentheses, the number of clonotypes responding to antigen endogenously processed by mini-LCLs. Samples of donor P01 were CD8-enriched before sequencing.






820




825

**Figure 4. CMV-specific TCR $\beta$  clonotypes dominate the peripheral T-cell repertoire of CMV-positive donors.** (A) The figure shows the proportion of reads of the 100 most frequent TCR $\beta$  clonotypes of CMV-positive donors P01-P08 and CMV-negative donors N01-N08 in peripheral blood *ex vivo*. TCR $\beta$  clonotypes that were identified as specific for CMV epitopes CRV, FRC, or TPR are shown as colored dots, clonotypes of unknown specificity as black dots. Because epitope RPH was not tested in donors P02 and N01-N08, it was omitted from this analysis. (B) Frequencies of CMV-specific TCR $\beta$  sequences in the *ex vivo* repertoires (left) and CD8-enriched repertoires (right) of CMV-positive donors P01-P08 as cumulative proportion of

reads. RPH-specific T cells were not investigated in donor P02 and such T cells are therefore  
830 not depicted in the plots.



835 **Figure 5. Usage of V $\beta$  and J $\beta$  gene segments in CMV epitope-specific T cells.** The left  
 840 semicircle of each chord diagram represents V $\beta$  gene segment usage (rainbow colors), the right  
 semicircle represents J $\beta$  usage (grayscale shades), and the chords indicate which gene segments  
 appear together in TCR $\beta$  sequences. Sizes of sectors and chords are proportional to the sum of  
 the number of nucleotide-unique antigen-specific TCR $\beta$  sequences in each of the donors P01-  
 P08. The most frequently used gene segments are labeled and the numbers below the plots show  
 how many TCR $\beta$  sequences were specific for each epitope.




**Figure 6. Frequency of public TCR $\beta$  families in peripheral T-cell repertoires of CMV-positive and CMV-negative donors.** (A) Cumulative proportion of TCR $\beta$  sequence reads for each individual TCR $\beta$  family in the *ex vivo* TCR $\beta$  repertoires of donors P01-P16 and N01-N09. Read frequencies for each of the 63 TCR $\beta$  sequences that form these families can be found in  
850 Supplementary Table 3. (B) Cumulative proportion of reads for all public or related TCR $\beta$  sequences with the same epitope specificity in our donor cohort and an independent HLA-B7-positive subcohort from Emerson et al. (48) (C) Cumulative proportion of TCR $\beta$  sequence reads of all public/related TCR $\beta$  sequences in CMV-positive (solid circles) and CMV-negative (hollow circles) donors in our cohort, and in HLA-B7-positive and HLA-B7-negative donors  
855 from Emerson et al. (Supplementary Table 3). Grey circles identify donors P01-P08 from whose repertoires the TCR $\beta$  sequences were originally derived. The dashed line indicates a possible cut-off to separate CMV-positive and CMV-negative donors in our cohort (F1 score = 1) and the B7-positive cohort of Emerson et al. (F1 score = 0.93). Red lines show the median cumulative read frequencies. P values were calculated with a two-tailed Mann-Whitney U test.

860

## Supplementary Material

- 865 **Supplementary Figure 1.** Criteria for identification of CMV-specific TCR $\beta$  clonotypes.
- Supplementary Table 1.** Donors, epitopes, and primers.
- Supplementary Table 2.** Sample metadata and specific TCR $\beta$  sequences.
- 870 **Supplementary Table 3.** Frequencies of 63 public or related TCR $\beta$  sequences in *ex vivo* repertoires of two independent HLA-matched and one HLA-mismatched donor cohort.



### Supplementary Figure 1. Criteria for identification of CMV-specific TCR $\beta$ clonotypes.

875 As an example, representative data from donor P01 for identification of CRV-specific T cells are shown. Diagrams on the left relate to the binary comparison of the CRV-stimulated sample and the TPR-stimulated sample (control peptide). Diagrams on the right relate to the comparison of the CRV-stimulated sample and the unstimulated PBMC sample. Only TCRs that fulfilled all criteria were categorized as CRV epitope-specific. In dot plots, a frequency of  
880 zero is plotted as a pseudofrequency of 0.5 reads. **(A)** Relative frequencies of TCR $\beta$  clonotypes. Red lines indicate the enrichment cut-off (diagonal line) and the specific sample read count cut-off (horizontal line). **(B)** The enrichment cut-off (red line) is defined as the local minimum of the weighted density distribution of the logarithm of clonotype enrichment. Clonotype enrichment is the ratio of clonotype frequencies in the CRV-stimulated sample and either  
885 control. **(C)** Read count cut-offs (red line) were defined as local minima of the distribution of the logarithms of clonotype counts, determined for clonotypes with a read count of 1 to 10 in the TPR-stimulated (left) or unstimulated (right) sample. The mean of these two cut-offs was used as the final specific sample read count cut-off. **(D)** Relative frequencies of TCR $\beta$  clonotypes as in A, but TCR $\beta$  clonotypes that fulfil all inclusion criteria for being CRV epitope-  
890 specific are shown in red.